BETHESDA, Md.--Scientists at the National Cancer Institute (NCI), the largest of the 17 biomedical research centers operated by the US National Institutes of Health, have spent the past decade crafting a bioinformatics program to facilitate the institute's efforts to discover cancer cures.

Since 1990, NCI has tested more than 70,000 compounds for activity against 60 cancer cell lines. At least 5 have entered human trials. More than 460,000 other compounds await testing. Along the way, NCI has developed an arsenal of diverse genomics-based drug discovery tools.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.